Director Ann D. Rhoads of Globus Medical Inc. filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 5,000 shares of Globus Medical common stock on the New York Stock Exchange.

Key Highlights

  • Proposed seller: Ann D. Rhoads, a director of Globus Medical Inc.
  • Shares proposed for sale: 5,000 shares of common stock, with an aggregate market value of $425,000.00, according to the filing.
  • Source of shares: The securities were acquired on June 4, 2026, via a stock option exercise from the issuer, with 25,000 units acquired at that time and payment made in cash.
  • Approximate sale date: November 4, 2026, through Raymond James & Associates, Inc., located in St. Petersburg, Florida.
  • 10b5-1 plan date: The filing indicates a plan adoption or instruction date of June 10, 2026.
  • Shares outstanding: The filing lists 134,261,914 shares of Globus Medical common stock outstanding.
  • Prior sales: The filing reports nothing to report for securities sold during the past three months.

Ann D. Rhoads Proposes Sale of Globus Medical Shares Acquired via Option Exercise

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 4, 2026, Ann D. Rhoads, a director of Globus Medical Inc. (NYSE:GMED), disclosed a proposed sale of 5,000 shares of the company's common stock. The filing lists an aggregate market value of $425,000.00 for the proposed transaction, with the approximate date of sale noted as November 4, 2026. The broker named in the filing is Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716.

The filing discloses that the shares proposed for sale were acquired on June 4, 2026, through a stock option exercise from the issuer, Globus Medical Inc., with 25,000 units acquired on that date. Payment was described as cash, made on June 4, 2026. The filing further indicates that a Rule 10b5-1 plan or trading instruction was adopted or given on June 10, 2026. The filer represents, by signing the notice, that she "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated in the filing's standard attestation language.

The notice was signed by Rashida Mitchell, described as a duly authorized representative of Raymond James & Associates, Inc., acting as attorney-in-fact for Ann D. Rhoads. No securities sold in the prior three months were reported, and Globus Medical Inc. is headquartered at 2560 General Armistead Avenue, Audubon, Pennsylvania 19403, with SEC File Number 001-35621.

What Was Disclosed

Globus Medical director Ann D. Rhoads filed a Form 144 on November 4, 2026, proposing to sell 5,000 shares of common stock valued at $425,000.00. The shares originated from a June 4, 2026 stock option exercise, and a 10b5-1 plan was adopted on June 10, 2026.